专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08790680B2 Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair 有权
标题翻译：用于组织和器官治疗和修复的干细胞基质的快速制备
公开(公告)号：US08790680B2
公开(公告)日：2014-07-29
申请号：US13046120
申请日：2011-03-11
申请人： Michael B. Chancellor , Johnny Huard , Christopher Capelli , Steve Chung , Michael S. Sacks
发明人： Michael B. Chancellor , Johnny Huard , Christopher Capelli , Steve Chung , Michael S. Sacks
IPC分类号： A61F2/00 , A61F13/00 , A61L27/36 , A61L27/38 , C12N5/071
CPC分类号： A61L27/3834 , A61K35/12 , A61L27/225 , A61L27/3629 , A61L27/3679 , A61L2430/22 , C12N5/0068 , C12N5/0658 , C12N5/0668 , C12N5/0697 , C12N2533/56 , C12N2533/74 , C12N2533/90 , C12N2533/92
摘要： A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition.
摘要翻译：描述了用于制备用于组织和器官修复的干细胞和生理上可接受的基质组合物的快速方法。与以前的组织工程材料相比，本发明的干细胞 - 基质组合物在用于体内应用之前不需要在体外长期孵育或培养。干细胞可以来自多种来源，并且在基质材料中可以是均质的，异质的，自体的和/或同种异体的。干细胞 - 基质组合物为实践者提供了服务点，其中干细胞和基质在使用前可以组合不久，从而减轻昂贵且冗长的制造过程。此外，干细胞为基质组合物提供独特的结构特性，可改善使用后的结果和愈合。使用从肌肉获得的干细胞可提供收缩性的基质组成。

2. 发明申请

US20110223139A1 RAPID PREPARATION OF STEM CELL MATRICES FOR USE IN TISSUE AND ORGAN TREATMENT AND REPAIR 有权
标题翻译：用于组织和组织治疗和修复的干细胞基质的快速制备
公开(公告)号：US20110223139A1
公开(公告)日：2011-09-15
申请号：US13046120
申请日：2011-03-11
申请人： Michael B. Chancellor , Johnny Huard , Christopher Capelli , Steve Chung , Michael S. Sacks
发明人： Michael B. Chancellor , Johnny Huard , Christopher Capelli , Steve Chung , Michael S. Sacks
IPC分类号： A61K35/34 , A61P17/02
CPC分类号： A61L27/3834 , A61K35/12 , A61L27/225 , A61L27/3629 , A61L27/3679 , A61L2430/22 , C12N5/0068 , C12N5/0658 , C12N5/0668 , C12N5/0697 , C12N2533/56 , C12N2533/74 , C12N2533/90 , C12N2533/92
摘要： A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition.
摘要翻译：描述了用于制备用于组织和器官修复的干细胞和生理上可接受的基质组合物的快速方法。与以前的组织工程材料相比，本发明的干细胞 - 基质组合物在用于体内应用之前不需要在体外长期孵育或培养。干细胞可以来自多种来源，并且在基质材料中可以是均质的，异质的，自体的和/或同种异体的。干细胞 - 基质组合物为实践者提供了服务点，其中干细胞和基质在使用前可以组合不久，从而减轻昂贵且冗长的制造过程。此外，干细胞为基质组合物提供独特的结构特性，可改善使用后的结果和愈合。使用从肌肉获得的干细胞可提供收缩性的基质组成。

3. 发明授权

US07906110B2 Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair 有权
标题翻译：用于组织和器官治疗和修复的干细胞基质的快速制备
公开(公告)号：US07906110B2
公开(公告)日：2011-03-15
申请号：US11138168
申请日：2005-05-25
申请人： Michael B. Chancellor , Johnny Huard , Christopher Capelli , Steve Chung , Michael S. Sacks
发明人： Michael B. Chancellor , Johnny Huard , Christopher Capelli , Steve Chung , Michael S. Sacks
IPC分类号： A01N65/00 , A61F13/00
CPC分类号： A61L27/3834 , A61K35/12 , A61L27/225 , A61L27/3629 , A61L27/3679 , A61L2430/22 , C12N5/0068 , C12N5/0658 , C12N5/0668 , C12N5/0697 , C12N2533/56 , C12N2533/74 , C12N2533/90 , C12N2533/92
摘要： The invention is directed to preparation of stem cell and physiologically acceptable matrix compositions. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition.
摘要翻译：本发明涉及干细胞和生理上可接受的基质组合物的制备。与以前的组织工程材料相比，本发明的干细胞基质组合物在使用体内应用之前不需要在体外长期孵育或培养。干细胞可以来自多种来源，并且在基质材料中可以是均质的，异质的，自体的和/或同种异体的。干细胞 - 基质组合物为实践者提供了服务点，其中干细胞和基质在使用前可以组合不久，从而减轻昂贵且冗长的制造过程。此外，干细胞为基质组合物提供独特的结构特性，可改善使用后的结果和愈合。使用从肌肉获得的干细胞可提供收缩性的基质组成。

4. 发明授权

US08986671B2 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof 有权
标题翻译：使用肌肉来源的祖细胞的软组织和骨增大和膨胀，其组合物和处理
公开(公告)号：US08986671B2
公开(公告)日：2015-03-24
申请号：US11505734
申请日：2006-08-17
申请人： Michael B. Chancellor , Johnny Huard , Christopher C. Capelli , Zhuqing Qu
发明人： Michael B. Chancellor , Johnny Huard , Christopher C. Capelli , Zhuqing Qu
IPC分类号： A61K35/34 , C12N5/077 , A61K35/12
CPC分类号： C12N5/0659 , A61K35/12 , A61K35/34 , C12N5/0658 , C12N2500/84 , C12N2501/70 , C12N2510/00 , C12N2533/54
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.
摘要翻译：本发明提供了肌肉衍生的祖细胞，其在移植到身体组织中后显示出长期存活，并且可以在引入（例如通过注射，移植或植入）之后增加软组织到软组织部位中。还提供了分离肌肉来源的祖细胞的方法，以及遗传修饰细胞用于基因转移治疗的方法。本发明进一步提供使用包含肌肉来源的祖细胞的组合物的方法，用于增加和膨胀哺乳动物，包括人类软组织，以治疗各种美容或功能状况，包括畸形，损伤，无力，疾病或功能障碍。特别地，本发明提供了用于皮肤病学，胃食管反流，膀胱输尿管反流，尿失禁，大便失禁，心力衰竭和心肌梗塞的治疗和改善。

5. 发明授权

US08685385B2 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof 有权
标题翻译：使用肌肉来源的祖细胞的软组织和骨增大和膨胀，其组合物和处理
公开(公告)号：US08685385B2
公开(公告)日：2014-04-01
申请号：US13038827
申请日：2011-03-02
申请人： Michael B. Chancellor , Johnny Huard , Christopher C. Capelli , Zhuqing Qu
发明人： Michael B. Chancellor , Johnny Huard , Christopher C. Capelli , Zhuqing Qu
IPC分类号： A61K35/34
CPC分类号： C12N5/0659 , A61K35/12 , A61K35/34 , C12N5/0658 , C12N2500/84 , C12N2501/70 , C12N2510/00 , C12N2533/54
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.
摘要翻译：本发明提供了肌肉衍生的祖细胞，其在移植到身体组织中后显示出长期存活，并且可以在引入（例如通过注射，移植或植入）之后增加软组织到软组织部位中。还提供了分离肌肉来源的祖细胞的方法，以及遗传修饰细胞用于基因转移治疗的方法。本发明进一步提供使用包含肌肉来源的祖细胞的组合物的方法，用于增加和膨胀哺乳动物，包括人类软组织，以治疗各种美容或功能状况，包括畸形，损伤，无力，疾病或功能障碍。特别地，本发明提供了用于皮肤病学，胃食管反流，膀胱输尿管反流，尿失禁，大便失禁，心力衰竭和心肌梗死的治疗和改善。

6. 发明授权

US08741277B2 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof 有权
公开(公告)号：US08741277B2
公开(公告)日：2014-06-03
申请号：US11505735
申请日：2006-08-17
申请人： Michael B. Chancellor , Johnny Huard , Christopher C. Capelli , Zhuqing Qu
发明人： Michael B. Chancellor , Johnny Huard , Christopher C. Capelli , Zhuqing Qu
IPC分类号： A61K35/34
CPC分类号： C12N5/0659 , A61K35/12 , A61K35/34 , C12N5/0658 , C12N2500/84 , C12N2501/70 , C12N2510/00 , C12N2533/54
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.

7. 发明申请

US20120109107A1 Muscle Derived Cells for the Treatment of Urinary Tract Pathologies and Methods of Making and Using the Same 有权
标题翻译：用于治疗尿道病理学的肌肉来源细胞及其制备和使用方法
公开(公告)号：US20120109107A1
公开(公告)日：2012-05-03
申请号：US13336332
申请日：2011-12-23
申请人： Michael B. Chancellor , Ronald Jankowski , Ryan Pruchnic , Johnny Huard
发明人： Michael B. Chancellor , Ronald Jankowski , Ryan Pruchnic , Johnny Huard
IPC分类号： A61M37/00 , A61P13/02 , C12N5/071 , A61K35/34
CPC分类号： C12N5/0658 , A61K35/12 , A61K35/34 , C12N2500/38 , C12N2501/105 , C12N2501/11 , C12N2501/115 , C12N2501/165 , C12N2501/39 , C12N2501/91
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for urinary incontinence and other urinary tract pathologies.
摘要翻译：本发明提供了肌肉衍生的祖细胞，其在移植到身体组织中后显示出长期存活，并且可以在引入（例如通过注射，移植或植入）之后增加软组织到软组织部位中。还提供了分离肌肉来源的祖细胞的方法，以及遗传修饰细胞用于基因转移治疗的方法。本发明还提供使用包含肌肉来源的祖细胞的组合物的方法，用于在治疗包括畸形，损伤，无力，疾病或功能障碍的各种功能状况的哺乳动物包括人类软组织的增加和膨胀中。特别地，本发明提供了治疗和改善尿失禁和其他尿路病变。

8. 发明授权

US08105834B2 Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using same 有权
标题翻译：肌肉衍生细胞用于治疗尿道病理及其制作和使用方法
公开(公告)号：US08105834B2
公开(公告)日：2012-01-31
申请号：US12013076
申请日：2008-01-11
申请人： Michael B. Chancellor , Ronald Jankowski , Ryan Pruchnic , Johnny Huard
发明人： Michael B. Chancellor , Ronald Jankowski , Ryan Pruchnic , Johnny Huard
IPC分类号： C12N5/02 , C12N5/071
CPC分类号： C12N5/0658 , A61K35/12 , A61K35/34 , C12N2500/38 , C12N2501/105 , C12N2501/11 , C12N2501/115 , C12N2501/165 , C12N2501/39 , C12N2501/91
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for urinary incontinence and other urinary tract pathologies.
摘要翻译：本发明提供了肌肉衍生的祖细胞，其在移植到身体组织中后显示出长期存活，并且可以在引入（例如通过注射，移植或植入）之后增加软组织到软组织部位中。还提供了分离肌肉来源的祖细胞的方法，以及遗传修饰细胞用于基因转移治疗的方法。本发明还提供使用包含肌肉来源的祖细胞的组合物的方法，用于在治疗包括畸形，损伤，无力，疾病或功能障碍的各种功能状况的哺乳动物包括人类软组织的增加和膨胀中。特别地，本发明提供了治疗和改善尿失禁和其他尿路病变。

9. 发明授权

US09617516B2 Muscle-derived cells (MDCs) for promoting and enhancing nerve repair and regeneration 有权
公开(公告)号：US09617516B2
公开(公告)日：2017-04-11
申请号：US10832542
申请日：2004-04-26
申请人： Michael B. Chancellor , Johnny Huard , Brandon Minnery , Chistopher C. Capelli
发明人： Michael B. Chancellor , Johnny Huard , Brandon Minnery , Chistopher C. Capelli
IPC分类号： C12N5/07 , C12N5/071 , C12N5/16 , C12N5/0789 , C12N5/077 , A61K35/34 , A61K35/12
CPC分类号： C12N5/0658 , A61K35/12 , A61K35/34
摘要： The present invention describes methods involving the use of muscle derived cells (MDCs), preferably obtained from skeletal muscle, to support the innervation and repair of damaged tissues and organs, particularly associated with nerve damage or neuropathy. The invention relates to MDCs for use in methods for promoting or enhancing innervation of nerve cells, particularly in the peripheral nervous system, and their ability to contribute to the development of neuronal tissue when MDCs are introduced at or near a tissue or organ site in need of repair due to injury, damage, disease, or dysfunction. Such methods are useful for the treatment of central and peripheral nervous system disorders and to alleviate, abate, or eliminate the symptoms of neurologic or neurodegenerative diseases in animals, particularly mammals, including humans. The methods are also useful for treating both nerve and muscle tissue following injury, damage, or dysfunction to these tissue types.

10. 发明授权

US08765120B2 Muscle-derived cells (MDCS) for augmenting or bulking urethral sphincter-muscle tissue 有权
标题翻译：肌肉衍生细胞（MDCS）用于增加或扩大尿道括约肌肌肉组织
公开(公告)号：US08765120B2
公开(公告)日：2014-07-01
申请号：US13025449
申请日：2011-02-11
申请人： Michael B. Chancellor , Johnny Huard
发明人： Michael B. Chancellor , Johnny Huard
IPC分类号： A61K35/34 , C12N5/077
CPC分类号： A61K35/34 , C12N5/0658 , C12N5/0659 , C12N2501/105 , C12N2501/113 , C12N2501/115 , C12N2501/13 , C12N2510/00 , C12N2510/04
摘要： The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-1, transforming growth factor-a, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.
摘要翻译：本发明提供肌肉衍生的细胞，优选成肌细胞和来自肌肉的干细胞，其被遗传工程化以含有和表达这种基因的一个或多个异源基因或功能区段，用于在肌肉骨骼的位点或附近递送编码的基因产物，骨，韧带，半月板，软骨或泌尿生殖系疾病，损伤，缺陷或功能障碍。本发明特别提供离体成肌细胞介导的人诱导型一氧化氮合酶的基因递送以及所产生的损伤部位周围及其周围的一氧化氮，作为降低泌尿生殖道功能障碍的治疗。肌肉骨骼系统的离体基因转移包括编码酸性成纤维细胞生长因子，碱性成纤维细胞生长因子，表皮生长因子，胰岛素样生长因子，血小板衍生生长因子，转化生长因子-1，转化生长因子-α，神经生长的基因因子和白细胞介素-1受体拮抗蛋白（IRAP），骨形态发生蛋白（BMPs），软骨来源的形态发生蛋白（CDMPs），血管内皮生长因子（VEGF）和声音刺猬蛋白。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式